OncLive® On Air S16 Ep11: Expert Illustrations & Commentaries: Translating the Science of Bispecific Antibodies in Solid Tumors – From Mechanisms to Emerging Data
Feb 26, 2026
John V. Heymach, MD, PhD, a thoracic oncology physician-scientist, and Anne S. Tsao, MD, MBA, a medical oncologist focused on thoracic immunotherapy, discuss bispecific antibodies. They cover PD-1/CTLA-4 platforms, VEGF–PD-1 mechanisms and trial data, and DLL3-directed T-cell engagers like tarlatimab. Conversation also touches on safety management and potential roles in thoracic cancers.
AI Snips
Chapters
Transcript
Episode notes
Bispecific Antibody Platform Explained
- Bispecific antibodies are a platform that either cross-link tumor antigens or redirect T cells to tumors for antitumor effects.
- T-cell engagers bind CD3 on T cells and a tumor antigen, while non-T-cell bispecifics cross-link receptors to induce tumor death.
Vilrestimig In Frontline Mesothelioma
- Vilrestimig (Medi-5752) targets PD‑1 and CTLA‑4 and is being tested with chemotherapy in frontline mesothelioma (EVOLVE Mesotrial).
- EVOLVE is a phase III registration trial with preliminary readout expected around 2028.
Rationale For PD‑1 CTLA‑4 Bispecifics
- PD‑1/CTLA‑4 bispecifics aim to combine complementary checkpoint biology in one molecule for coordinated immune activation.
- The goal is improved therapeutic index and durability versus giving two separate agents.